Researchers developed a precise mass spectrometry assay that can separately quantify different forms of synuclein proteins in brain tissue, improving Parkinson's disease research tools.
4-in-1 analysisMeasures total alpha-synuclein, species-specific forms, combined alpha/beta, and post-translational modifications in a single run
What the researchers found
The MRM LC-MS/MS assay quantifies total alpha-synuclein, species-specific contributions, combined alpha/beta-synuclein, and post-translational modification signatures in a single streamlined analysis with wide linear range.
Why it matters
Better tools to measure synuclein proteins are essential for Parkinson's disease research. This method provides more detailed and reliable measurements than existing techniques, potentially accelerating preclinical drug development.
The numbers in context
6 proteotypic peptides; 3 species-specific; 3 conserved; linear over ≥1 order of magnitude
How the study worked
Development and validation of a multiple reaction monitoring LC-MS/MS assay using proteolytic digestion of six proteotypic peptides, labeled internal standards, and external calibration curves. Validated in M83 transgenic PD mouse brain tissue versus wild-type controls.
Who was studied
M83 transgenic PD mice and wild-type littermate controls
What this study cannot tell us
Validated only in transgenic mouse brain tissue with a small sample size. Application to human tissues and biofluids like cerebrospinal fluid remains to be demonstrated. The method measures soluble synucleins but may not capture aggregated forms.
How to read the evidence
Rated preliminary because while the analytical method is well-developed, it has only been validated in a small number of transgenic mouse samples and has not yet been applied to human tissue.
When this study was published
Published in 2020, this methods paper addresses ongoing analytical challenges in synuclein research that remain relevant today.
The bigger picture
Synuclein aggregation is central to Parkinson's disease pathology. Having precise tools to measure different synuclein forms could improve our understanding of disease progression and help evaluate whether experimental therapies actually reduce pathological synuclein levels.
Questions still open
- Can this assay be adapted to measure synuclein in human cerebrospinal fluid or blood for diagnostic purposes?
- How well does the method detect aggregated or phosphorylated synuclein forms most relevant to disease?
- Could this platform be used to monitor treatment response in Parkinson's disease clinical trials?
Common questions
What are synucleins and why do they matter in Parkinson's disease?
Why is this method better than existing protein measurement techniques?
Read the original research
Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.
Journal of Parkinson's disease, 10(2), 613-621
Citation
Singh, Serena; Khayachi, Anouar; Milnerwood, Austen J; DeMarco, Mari L. (2020). Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinson's Disease.. Journal of Parkinson's disease, 10(2), 613-621. https://doi.org/10.3233/JPD-191835